{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:47:10Z","timestamp":1791312430502,"version":"4.3.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009873","name":"Regione autonoma della Sardegna","doi-asserted-by":"crossref","award":["CRP 3360"],"award-info":[{"award-number":["CRP 3360"]}],"id":[{"id":"10.13039\/501100009873","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ANR grant","award":["11-BS07-032"],"award-info":[{"award-number":["11-BS07-032"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.bcp.2015.01.010","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T21:24:01Z","timestamp":1422912241000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The purine analog fludarabine acts as a cytosolic 5\u2032-nucleotidase II inhibitor"],"prefix":"10.1016","volume":"94","author":[{"given":"F.","family":"Cividini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chaloin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Allegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Camici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cros-Perrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.P.","family":"Jordheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.01.010_bib0180","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/bj1620611","article-title":"A kinetic study of the soluble 5\u2032-nucleotidase of rat liver","volume":"162","author":"Van den Berghe","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2015.01.010_bib0185","first-page":"12","article-title":"New antimetabolites in the treatment of human malignancies","volume":"19","author":"Cheson","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2015.01.010_bib0195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2015.01.010_bib0200","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V98.6.1922","article-title":"Expression of high Km 5\u2032-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia","volume":"98","author":"Galmarini","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.01.010_bib0205","doi-asserted-by":"crossref","first-page":"46195","DOI":"10.1074\/jbc.R300032200","article-title":"Mammalian 5\u2032-nucleotidases","volume":"278","author":"Bianchi","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2015.01.010_bib0210","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/1357-2725(95)00171-9","article-title":"The phosphotransferase activity of cytosolic 5\u2032-nucleotidase; a purine analog phosphorylating enzyme","volume":"28","author":"Banditelli","year":"1996","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0215","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/1042819031000077142","article-title":"Role of IMP-selective 5\u2032-nucleotidase (cN-II) in hematological malignancies","volume":"44","author":"Galmarini","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bcp.2015.01.010_bib0220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2007.01.003","article-title":"Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells","volume":"55","author":"Giovannetti","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bcp.2015.01.010_bib0225","first-page":"1699","article-title":"The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia","volume":"90","author":"Galmarini","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2015.01.010_bib0230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04386.x","article-title":"Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine","volume":"122","author":"Galmarini","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0235","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0006-2952(03)00290-9","article-title":"Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy","volume":"66","author":"Mazzon","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0240","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/15257770500458027","article-title":"F-ara-AMP is a substrate of cytoplasmic 5\u2032-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation","volume":"25","author":"Jordheim","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.bcp.2015.01.010_bib0245","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.leukres.2007.02.006","article-title":"What does over-expression of cN-II enzyme signify in haematological malignancies?","volume":"31","author":"Galmarini","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.bcp.2015.01.010_bib0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.111.182873","article-title":"Genetic variants in cytosolic 5\u2032-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia","volume":"339","author":"Mitra","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2015.01.010_bib0255","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"4","author":"Meyer","year":"2013","journal-title":"Nat Gen"},{"key":"10.1016\/j.bcp.2015.01.010_bib0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/ehm.13.28","article-title":"Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?","volume":"6","author":"Meyer","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0265","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2015.01.010_bib0270","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.2174\/0929867311320340007","article-title":"On the physiological role of cytosolic 5\u2032-nucleotidase II (Cn-II): pathological and therapeutical implications","volume":"34","author":"Tozzi","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bcp.2015.01.010_bib0275","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bcp.2012.11.024","article-title":"Identification and characterization of inhibitors of cytoplasmic 5\u2032-nucleotidase cN-II issued from virtual screening","volume":"85","author":"Jordheim","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0280","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0163-7258(00)00086-3","article-title":"Basis for effective combination cancer chemotherapy with antimetabolites","volume":"87","author":"Peters","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2015.01.010_bib0285","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","article-title":"Analysis of drug interactions","volume":"731","author":"Bijnsdorp","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0290","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1111\/j.1742-4658.2010.07891.x","article-title":"Active and regulatory sites of cytosolic 5\u2032-nucleotidase","volume":"277","author":"Pesi","year":"2010","journal-title":"FEBS J"},{"key":"10.1016\/j.bcp.2015.01.010_bib0295","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0003-2697(88)90002-4","article-title":"A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases","volume":"168","author":"Chifflet","year":"1988","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bcp.2015.01.010_bib0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0305","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jbt.2570090108","article-title":"Cytosolic 5\u2032-nucleotidase\/nucleoside phosphotransferase: a nucleoside analog activating enzyme?","volume":"9","author":"Turriani","year":"1994","journal-title":"J Biochem Toxicol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0310","doi-asserted-by":"crossref","first-page":"17828","DOI":"10.1074\/jbc.M700917200","article-title":"Crystal structure of human cytosolic 5\u2032-nucleotidase II: insights into allosteric regulation and substrate recognition","volume":"282","author":"Wallden","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2015.01.010_bib0315","doi-asserted-by":"crossref","first-page":"e1002295","DOI":"10.1371\/journal.pcbi.1002295","article-title":"Structural insights into the inhibition of cytosolic 5\u2032-nucleotidase II (cN-II) by ribonucleoside 5\u2032-monophosphate analogues","volume":"7","author":"Gallier","year":"2011","journal-title":"PLoS Comp Biol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0320","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jmb.2011.02.059","article-title":"Structural basis for the allosteric regulation and substrate recognition of human cytosolic 5\u2032-nucleotidase II","volume":"408","author":"Wallden","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0325","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1042\/bj3170797","article-title":"Mechanism of the reaction catalysed by cytosolic 5\u2032-nucleotidase\/phosphotransferase: formation of a phosphorylated intermediate","volume":"317","author":"Baiocchi","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2015.01.010_bib0330","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0026-895X(25)09195-3","article-title":"Phosphorylation of 2\u2032,3\u2032-dideoxyinosine by cytosolic 5\u2032-nucleotidase of human lymphoid cells","volume":"36","author":"Johnson","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0335","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/0006-291X(90)90827-A","article-title":"Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2\u2032,3\u2032-dideoxyguanosine","volume":"171","author":"Ahluwalia","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2015.01.010_bib0340","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4615-7703-4_39","article-title":"Cytosolic 5\u2032-nucleotidase\/phosphotransferase of human colon carcinoma","volume":"309B","author":"Tozzi","year":"1992","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.bcp.2015.01.010_bib0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063914","article-title":"Expression of bovine cytosolic 5\u2032-nucleotidase (cN-II) in yeast: nucleotide pools disturbance and its consequences on growth and homologous recombination","author":"Allegrini","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bcp.2015.01.010_bib0350","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.bbamcr.2008.03.018","article-title":"Knockdown of cytosolic 5\u2032-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells","volume":"1783","author":"Careddu","year":"2008","journal-title":"Biochim Biophys Acta"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T05:59:45Z","timestamp":1747547985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0006295215000799"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.01.010","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The purine analog fludarabine acts as a cytosolic 5\u2032-nucleotidase II inhibitor","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}